# CanSino Biologics Inc. clinical trials: 41 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 41 trials with CanSino Biologics Inc. as lead sponsor, 6 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by CanSino Biologics Inc.: 41 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/cansino-biologics-inc

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 41
- Recruiting or not yet: 6
- Read on: November 19, 2026

## Trials

The 25 newest of 41, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| September 8, 2026 | NCT07807033 | Observation of Immune Persistence in a Clinical Trial of an Adsorbed Tetanus Vaccine | CanSino Biologics Inc. | Observational | Not yet recruiting | Tetanus | 240 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07807033) |
| August 4, 2026 | NCT07744347 | A Clinical Study on Immunogenicity Persistence of Adsorbed 5-component Acellular Pertussis, Diphtheria and Tetanus Combined Vaccine | CanSino Biologics Inc. | Observational | Not yet recruiting | Diphtheria, Tetanus, Pertussis | 160 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07744347) |
| August 3, 2026 | NCT07743411 | A Clinical Trial of the ACYW135 Group Meningococcal Polysaccharide-Conjugated Vaccine (CRM197 Vector) | CanSino Biologics Inc. | Observational | Not yet recruiting | Epidemic Meningitis | 180 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07743411) |
| June 15, 2026 | NCT07648641 | A Clinical Trial of the 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (CRM197/Tetanus Toxoid) | CanSino Biologics Inc. | Observational | Not yet recruiting | Pneumococcal Infections, Streptococcal Infections, Bacterial Infections | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07648641) |
| May 22, 2026 | NCT07600983 | Clinical Trial of the 24-valent Pneumococcal Polysaccharide Conjugate Vaccine (CRM197/Tetanus Toxoid) | CanSino Biologics Inc. | Phase 1/2 | Recruiting | Streptococcus Pneumoniae Infection | 854 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07600983) |
| October 2, 2025 | NCT07203755 | Clinical Trial of the Adsorbed Acellular Pertussis (Tricomponent) DTaP-Haemophilus Influenzae Type b (Conjugate)-ACYW135 Group... | CanSino Biologics Inc. | Phase 1 | Recruiting | Diphtheria, Tetanus and Acellular Pertussis, Epidemic Meningitis, Haemophilus Influenzae Type B Infection | 260 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07203755) |
| June 12, 2025 | NCT07017777 | A Study to Evaluate the Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine (PCV13i) in Healthy Infants Aged 2 Months... | CanSino Biologics Inc. | Phase 3 | Active not recruiting | Pneumococcal Infections, Streptococcal Infections, Bacterial Infections | 600 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07017777) |
| March 4, 2025 | NCT06857370 | Inter-lot Consistency Clinical Trial of Adsorbed Cell-free DTP (Three-component) Combined Vaccine | CanSino Biologics Inc. | Phase 3 | Active not recruiting | Diphtheria, Tetanus and Acellular Pertussis | 780 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06857370) |
| December 13, 2024 | NCT06732583 | A Study to Evaluate the Safety and Immunogenicity of Ad5-105K in Adults Aged 18 to 49 Years | CanSino Biologics Inc. | Phase 1 | Active not recruiting | Tuberculosis | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06732583) |
| November 27, 2024 | NCT06708286 | A Clinical Trials of Adsorbed Cell-free DPT Vaccine (Five-component) | CanSino Biologics Inc. | Phase 2/3 | Completed | Diphtheria, Tetanus, Pertussis | 1,820 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06708286) |
| November 21, 2024 | NCT06700148 | A Clinical Trial of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector) in 7 to 17 Year Olds | CanSino Biologics Inc. | Phase 3 | Completed | Meningococcal Meningitis | 840 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06700148) |
| October 1, 2024 | NCT06621654 | Clinical Trial of Lyophilized Haemophilus Influenzae Type b Conjugate Vaccine | CanSino Biologics Inc. | Phase 1 | Active not recruiting | Haemophilus Influenzae Type B Infection | 160 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06621654) |
| August 29, 2024 | NCT06577298 | A Study to Evaluate the Safety and Immunogenicity of VLP-Polio in Infants and Toddlers | CanSino Biologics Inc. | Phase 1/2 | Active not recruiting | Poliomyelitis | 480 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06577298) |
| April 29, 2024 | NCT06389513 | Clinical Study of the Safety of Menhycia® in 3-Month-Old Infants | CanSino Biologics Inc. | Phase 4 | Completed | Epidemic Meningitis | 3,011 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06389513) |
| January 26, 2024 | NCT06226714 | A Clinical Trial of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector) in 18-59 Year Olds | CanSino Biologics Inc. | Phase 3 | Active not recruiting | Meningococcal Meningitis | 840 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06226714) |
| November 14, 2023 | NCT06131554 | A Clinical Trial to Evaluate the Immunogenicity and Safety of Group ACYW135 Meningococcal Conjugate Vaccine (CRM197) in Adults Aged 18 to... | CanSino Biologics Inc. | Phase 3 | Completed | Meningococcal Meningitis | 1,480 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06131554) |
| November 9, 2023 | NCT06123663 | A Study to Evaluate the Safety and Immunogenicity of a Single Dose of Adsorbed Tetanus Vaccine in a Population Aged 18 Years and Over | CanSino Biologics Inc. | Phase 1 | Completed | Tetanus | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06123663) |
| November 7, 2023 | NCT06120751 | A Clinical Trial to Evaluate the Safety and Immunogenicity of a Single Dose of Adsorbed Tetanus Vaccine in a Population Aged 18 Years and... | CanSino Biologics Inc. | Phase 3 | Completed | Tetanus | 1,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06120751) |
| October 26, 2023 | NCT06101173 | A Study to Evaluate the Safety and Immunogenicity of Recombinant Trivalent Poliomyelitis Vaccine (Sf-RVN Cell) in Healthy Adults | CanSino Biologics Inc. | Phase 1 | Completed | Poliomyelitis | 72 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06101173) |
| September 28, 2023 | NCT06056050 | A Clinical Trial of Adsorbed Cell-free DPT Vaccine (5-component) (for People Aged 6 Years and Above) | CanSino Biologics Inc. | Phase 1 | Completed | Diphtheria, Tetanus, Pertussis | 180 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06056050) |
| August 25, 2023 | NCT06011200 | A Clinical Trial of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector) in a 4 to 6 Year-old Population | CanSino Biologics Inc. | Phase 3 | Completed | Epidemic Meningitis | 1,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06011200) |
| August 14, 2023 | NCT05991427 | A Study to Evaluate the Safety and Immunogenicity of ChAdOx1-VZV in Healthy Adults Aged 50-65 Years | CanSino Biologics Inc. | Phase 1 | Completed | Herpes Zoster | 65 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05991427) |
| July 19, 2023 | NCT05951725 | A Clinical Trial of Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed(DTcP) | CanSino Biologics Inc. | Phase 3 | Active not recruiting | Diphtheria, Tetanus and Acellular Pertussis | 2,520 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05951725) |
| July 7, 2023 | NCT05935176 | Phase IV Clinical Study of Immunogenicity of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector) | CanSino Biologics Inc. | Phase 4 | Active not recruiting | Epidemic Meningitis | 660 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05935176) |
| November 21, 2022 | NCT05622942 | Clinical Trial of Recombinant Pneumococcal Protein Vaccine | CanSino Biologics Inc. | Phase 1 | Completed | Pneumonia, Respiratory Tract Diseases, Respiratory Tract Infections | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05622942) |

## By phase

| Phase | Trials |
| --- | --- |
| Early phase 1 | 1 |
| Phase 1 | 12 |
| Phase 1/2 | 4 |
| Phase 2 | 2 |
| Phase 2/3 | 1 |
| Phase 3 | 14 |
| Phase 4 | 2 |
| Not applicable | 1 |
| Observational | 4 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 23 |
| Active not recruiting | 8 |
| Not yet recruiting | 4 |
| Recruiting | 2 |
| Withdrawn | 2 |
| Terminated | 1 |
| Unknown | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| COVID-19 | 12 |
| Tetanus | 10 |
| Alzheimer Disease 5 | 8 |
| Meningitis, Meningococcal | 8 |
| Diphtheria | 7 |
| Pneumococcal Infections | 5 |
| Whooping Cough | 4 |
| Streptococcal Infections | 4 |
| Bacterial Infections | 4 |
| Respiratory Aspiration | 4 |
| Infections | 2 |
| Pneumonia | 2 |
| Respiratory Tract Diseases | 2 |
| Respiratory Tract Infections | 2 |
| Haemophilus Infections | 2 |
| Poliomyelitis | 2 |
| Tuberculosis | 1 |
| Herpes Zoster | 1 |
| Chickenpox | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Water heater installers in the United States](https://specstream.ai/data/businesses/water-heater-installers/united-states)
- [Valet services in the United States](https://specstream.ai/data/businesses/valet-services/united-states)
- [Transcription services in the United States](https://specstream.ai/data/businesses/transcription-services/united-states)
- [Test preparation centers in the United States](https://specstream.ai/data/businesses/test-preparation-centers/united-states)
- [Surgery centers in the United States](https://specstream.ai/data/businesses/surgery-centers/united-states)
- [Specialty hospitals in the United States](https://specstream.ai/data/businesses/specialty-hospitals/united-states)
